Cargando…
Pathogenesis, Intervention, and Current Status of Drug Development for Sarcopenia: A Review
Sarcopenia refers to the loss of muscle strength and mass in older individuals and is a major determinant of fall risk and impaired ability to perform activities of daily living, often leading to disability, loss of independence, and death. Owing to its impact on morbidity, mortality, and healthcare...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10295434/ https://www.ncbi.nlm.nih.gov/pubmed/37371730 http://dx.doi.org/10.3390/biomedicines11061635 |
_version_ | 1785063419879096320 |
---|---|
author | Jang, Jung Yoon Kim, Donghwan Kim, Nam Deuk |
author_facet | Jang, Jung Yoon Kim, Donghwan Kim, Nam Deuk |
author_sort | Jang, Jung Yoon |
collection | PubMed |
description | Sarcopenia refers to the loss of muscle strength and mass in older individuals and is a major determinant of fall risk and impaired ability to perform activities of daily living, often leading to disability, loss of independence, and death. Owing to its impact on morbidity, mortality, and healthcare expenditure, sarcopenia in the elderly has become a major focus of research and public policy debates worldwide. Despite its clinical importance, sarcopenia remains under-recognized and poorly managed in routine clinical practice, partly owing to the lack of available diagnostic testing and uniform diagnostic criteria. Since the World Health Organization and the United States assigned a disease code for sarcopenia in 2016, countries worldwide have assigned their own disease codes for sarcopenia. However, there are currently no approved pharmacological agents for the treatment of sarcopenia; therefore, interventions for sarcopenia primarily focus on physical therapy for muscle strengthening and gait training as well as adequate protein intake. In this review, we aimed to examine the latest information on the epidemiology, molecular mechanisms, interventions, and possible treatments with new drugs for sarcopenia. |
format | Online Article Text |
id | pubmed-10295434 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-102954342023-06-28 Pathogenesis, Intervention, and Current Status of Drug Development for Sarcopenia: A Review Jang, Jung Yoon Kim, Donghwan Kim, Nam Deuk Biomedicines Review Sarcopenia refers to the loss of muscle strength and mass in older individuals and is a major determinant of fall risk and impaired ability to perform activities of daily living, often leading to disability, loss of independence, and death. Owing to its impact on morbidity, mortality, and healthcare expenditure, sarcopenia in the elderly has become a major focus of research and public policy debates worldwide. Despite its clinical importance, sarcopenia remains under-recognized and poorly managed in routine clinical practice, partly owing to the lack of available diagnostic testing and uniform diagnostic criteria. Since the World Health Organization and the United States assigned a disease code for sarcopenia in 2016, countries worldwide have assigned their own disease codes for sarcopenia. However, there are currently no approved pharmacological agents for the treatment of sarcopenia; therefore, interventions for sarcopenia primarily focus on physical therapy for muscle strengthening and gait training as well as adequate protein intake. In this review, we aimed to examine the latest information on the epidemiology, molecular mechanisms, interventions, and possible treatments with new drugs for sarcopenia. MDPI 2023-06-04 /pmc/articles/PMC10295434/ /pubmed/37371730 http://dx.doi.org/10.3390/biomedicines11061635 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Jang, Jung Yoon Kim, Donghwan Kim, Nam Deuk Pathogenesis, Intervention, and Current Status of Drug Development for Sarcopenia: A Review |
title | Pathogenesis, Intervention, and Current Status of Drug Development for Sarcopenia: A Review |
title_full | Pathogenesis, Intervention, and Current Status of Drug Development for Sarcopenia: A Review |
title_fullStr | Pathogenesis, Intervention, and Current Status of Drug Development for Sarcopenia: A Review |
title_full_unstemmed | Pathogenesis, Intervention, and Current Status of Drug Development for Sarcopenia: A Review |
title_short | Pathogenesis, Intervention, and Current Status of Drug Development for Sarcopenia: A Review |
title_sort | pathogenesis, intervention, and current status of drug development for sarcopenia: a review |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10295434/ https://www.ncbi.nlm.nih.gov/pubmed/37371730 http://dx.doi.org/10.3390/biomedicines11061635 |
work_keys_str_mv | AT jangjungyoon pathogenesisinterventionandcurrentstatusofdrugdevelopmentforsarcopeniaareview AT kimdonghwan pathogenesisinterventionandcurrentstatusofdrugdevelopmentforsarcopeniaareview AT kimnamdeuk pathogenesisinterventionandcurrentstatusofdrugdevelopmentforsarcopeniaareview |